We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

63 hedge funds and large institutions have $50.2M invested in Outlook Therapeutics in 2021 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 14

66% more capital invested

Capital invested by funds: $30.3M → $50.2M (+$19.9M)

29% more funds holding

Funds holding: 49 → 63 (+14)

0.19% more ownership

Funds ownership: 0.39% → 0.58% (+0.19%)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

Holders
63
Holders Change
+14
Holders Change %
+28.57%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
11
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.3M
2
State Street
State Street
Massachusetts
+$3.11M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.8M
4
Northern Trust
Northern Trust
Illinois
+$1.64M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.09M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.87M
2
Two Sigma Investments
Two Sigma Investments
New York
-$820K
3
Millennium Management
Millennium Management
New York
-$450K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$373K
5
ECM
ExodusPoint Capital Management
New York
-$319K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$14.3M +$9.3M +200,570 +230%
Vanguard Group
2
Vanguard Group
Pennsylvania
$11.5M +$1.09M +23,457 +11%
LA
3
LVW Advisors
New York
$4.34M – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$3.77M +$1.8M +38,720 +104%
State Street
5
State Street
Massachusetts
$3.34M +$3.11M +67,126 New
Two Sigma Investments
6
Two Sigma Investments
New York
$2.22M -$820K -17,668 -28%
Northern Trust
7
Northern Trust
Illinois
$2.19M +$1.64M +35,346 +407%
Two Sigma Advisers
8
Two Sigma Advisers
New York
$1.73M +$215K +4,625 +15%
Axa
9
Axa
France
$778K -$236K -5,085 -25%
LNC
10
Lincoln National Corp
Pennsylvania
$631K +$588K +12,665 New
Bank of New York Mellon
11
Bank of New York Mellon
New York
$578K +$318K +6,865 +144%
Charles Schwab
12
Charles Schwab
California
$548K +$431K +9,281 +539%
N
13
Nuveen
North Carolina
$468K +$435K +9,383 New
IA
14
IndexIQ Advisors
New York
$448K -$10K -216 -2%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$444K – – –
Morgan Stanley
16
Morgan Stanley
New York
$311K +$234K +5,052 +428%
California State Teachers Retirement System (CalSTRS)
17
California State Teachers Retirement System (CalSTRS)
California
$302K +$281K +6,062 New
Citadel Advisors
18
Citadel Advisors
Florida
$191K -$232K -5,001 -57%
New York State Common Retirement Fund
19
New York State Common Retirement Fund
New York
$187K +$174K +3,750 New
Jane Street
20
Jane Street
New York
$160K +$148K +3,198 New
Osaic Holdings
21
Osaic Holdings
Arizona
$158K -$3.62K -78 -2%
Deutsche Bank
22
Deutsche Bank
Germany
$129K +$121K +2,600 New
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$118K +$95.9K +2,067 +689%
RhumbLine Advisers
24
RhumbLine Advisers
Massachusetts
$115K +$107K +2,299 New
AQR Capital Management
25
AQR Capital Management
Connecticut
$90K +$83.5K +1,800 New
1
2 3 4

OTLK Hedge Fund Activity: Q2 2021 in Review

63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2021, worth a combined $50.2M — up 66% from $30.3M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new OTLK positions and 14 closed out — a net gain of 14 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $9.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.87M sold.

  • 63 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2021, up from 49 in Q1 2021.
  • Funds reported $50.2M of Outlook Therapeutics stock for Q2 2021, up 66% quarter-over-quarter.
  • 28 funds opened new Outlook Therapeutics positions in Q2 2021 and 14 closed out, a net change of +14 holders.
  • The largest Outlook Therapeutics buyer in Q2 2021 was BlackRock, an estimated $9.3M added.
  • The largest Outlook Therapeutics seller in Q2 2021 was Renaissance Technologies, an estimated $1.87M sold.

Based on aggregated 13F filings for Q2 2021.